3M Company vs Zoetis Inc — how do they compare? 3M Company trades at $183.32 (market cap $94.44B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: 3M Company is far larger — about 3× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| MMM | ZTS | |
|---|---|---|
Market Cap | $94.44B | $31.14B |
Sector | Industrials | Health |
52-Week High | $183.13 | $156.76 |
52-Week Low | $141.10 | $71.91 |
Enterprise Value | $103.67B | $38.70B |
Dividend Yield | 1.7% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $184.15, up 1.16% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings, beating estimates and raising full-year guidance, driven by growth in Safety & Industrial and Transport & Electronics segments. Financial health is solid with a net income margin of 11.9% and robust cash flow, though valuation ratios like P/E of 32.53 appear elevated. Recent news highlights innovation in high-growth verticals and a partnership with Microsoft on EBO technology.
The outlook for MMM is positive due to operational improvements and raised guidance, but risks include high valuation, ongoing litigation, and macroeconomic pressures. Analyst sentiment is mixed with a consensus price target of $173.00 below the current price, suggesting cautious optimism. Investors should weigh strong fundamentals against potential headwinds for balanced decision-making.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Latest headlines on both assets
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →